首页> 外文期刊>Journal of interventional cardiology >Low Power Ultrasound Delivered Through a PTCA-Like Guidewire: Preclinical Feasibility and Safety of a Novel Technology for Intracoronary Thrombolysis.
【24h】

Low Power Ultrasound Delivered Through a PTCA-Like Guidewire: Preclinical Feasibility and Safety of a Novel Technology for Intracoronary Thrombolysis.

机译:通过类似PTCA的导线提供的低功率超声:一种用于冠状动脉内溶栓的新技术的临床前可行性和安全性。

获取原文
获取原文并翻译 | 示例
       

摘要

Background: Low power ultrasound delivered through an angioplasty-like guidewire may be effective for intracoronary thrombolysis. We evaluated the preclinical feasibility and safety of such wire. Methods and Results: In 15 anesthetized Yucatan minipigs, the ultrasonic wire was advanced percutaneously into all three coronaries. Each coronary was randomized to long activation (6 minutes), short activation (3 minutes), or control (3 minutes indwelling, no activation). The energy delivered was 0.14 +/- 0.01 W/cm of active length (20 kHz). No changes in heart rate, rhythm, or arterial pressure occurred during wire positioning or activation. Mean lumen diameter (MLD) by quantitative angiography was not significantly different pre- and postintervention (2.36 +/- 0.12 mm vs 2.36 +/- 0.11 mm for long activation, P = 0.96; 2.33 +/- 0.15 mm vs 2.34 +/- 0.14 mm for short activation, P = 0.54; 2.30 +/- 0.12 mm vs 2.33 +/- 0.12 mm for control, P = 0.21). There were no angiographic stenoses at 60 or 90 days follow-up. Compared with baseline, MLD at follow-up increased in all the three groups (2.40 +/- 0.13 mm vs 2.53 +/- 0.11 mm, P = 0.004 for long activation; 2.37 +/- 0.17 mm vs 2.52 +/- 0.14 mm, P = 0.023 for short activation; 2.20 +/- 0.12 mm vs 2.33 +/- 0.11 mm, P = 0.001 for the control group). By histology, there were no clinically significant pathologic changes in coronary morphology. Conclusion: Use of a transverse cavitation therapeutic wire is feasible and well tolerated acutely in the normal porcine coronary. At 60 and 90 days, no angiographically apparent damage, no clinically significant pathologic changes, and no adverse events were seen. This technology may be safely used during percutaneous coronary intervention. Further studies are justified to evaluate its efficacy for intracoronary thrombus ablation.
机译:背景:通过血管成形术导丝传送的低功率超声可能对冠状动脉内溶栓有效。我们评估了这种线的临床前可行性和安全性。方法和结果:在15头麻醉的尤卡坦小型猪中,将超声线经皮推入所有三个冠状动脉。每个冠状动脉被随机分为长激活(6分钟),短激活(3分钟)或对照(留置3分钟,无激活)。输送的能量为有效长度(20 kHz)的0.14 +/- 0.01 W / cm。导线放置或激活过程中,心率,心律或动脉压均未发生变化。定量血管造影术的平均管腔直径(MLD)在干预前后均无显着差异(2.36 +/- 0.12 mm与长期激活的2.36 +/- 0.11 mm,P = 0.96; 2.33 +/- 0.15 mm与2.34 +/-短时激活为0.14毫米,P = 0.54; 2.30 +/- 0.12毫米,而对照为2.33 +/- 0.12毫米,P = 0.21)随访60或90天无血管狭窄。与基线相比,所有三组的MLD随访均增加(2.40 +/- 0.13毫米vs 2.53 +/- 0.11毫米,长时间激活P = 0.004; 2.37 +/- 0.17毫米vs 2.52 +/- 0.14毫米,P = 0.023(短暂激活); 2.20 +/- 0.12 mm与2.33 +/- 0.11 mm,对照组P = 0.001)。根据组织学,冠状动脉形态没有临床上明显的病理变化。结论:在常规猪冠状动脉中使用横空化治疗线是可行的,并且具有很好的耐受性。在60和90天时,没有血管造影上的明显损害,没有临床上显着的病理变化,也没有观察到不良事件。经皮冠状动脉介入治疗期间可安全使用该技术。有理由进行进一步研究以评估其对冠状动脉内血栓消融的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号